New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
09:03 EDTABTAbbott receives CE Mark for TECNIS Symfony extended range for cataract patients
Abbott announced it has received CE Marking in Europe for the TECNIS Symfony Extended Range of Vision intraocular lens for the treatment of cataract patients who may also have a diminished ability to focus on near objects. Standard IOLs can be used in cataract treatment to improve distance vision, but the TECNIS Symfony IOL is a first-of-its kind lens that is intended to provide patients a continuous range of vision including far, intermediate and near distances with reduced incidence of halo and glare comparable to a monofocal lens.
News For ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 22, 2014
18:00 EDTABTUS files civil suit against Omnicare for alleged Abbott kickbacks
The United States has filed a civil False Claims Act complaint against Omnicare (OCR) alleging that it solicited and received millions of dollars in kickbacks from pharmaceutical manufacturer Abbott Laboratories (ABT), the Justice Department announced. Omnicare is the nationís largest provider of pharmaceuticals and pharmacy consulting services to nursing homes. Federal regulations designed to protect nursing home residents from unnecessary drugs require nursing homes to retain consulting pharmacists such as those provided by Omnicare to ensure that residentsí drug prescriptions are appropriate. Reference Link
December 12, 2014
11:19 EDTABTAbbott board increases quarterly dividend to 24c from 22c
The board of Abbott increased the company's quarterly common dividend to 24c per share from 22c per share. The cash dividend is payable Feb. 13, 2015, to shareholders of record at the close of business on Jan. 15, 2015.
December 11, 2014
05:24 EDTABTAbbott IRIDICA now available in Europe
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use